Holoclar - an overview | ScienceDirect Topics

May 23, 2023 · Holoclar was developed based on more than twenty years of research by a team of internationally renowned scientists in the field of epithelial stem cell biology.

Jul 8, 2025 · Holoclar is a type of advanced therapy product called a ‘tissue engineered product’. It consists of cells taken from the patient’s limbus (at the edge of the cornea) and then grown in a …

Feb 23, 2015 · Chiesi, a privately held Italian company, has received approval in the EU for Holoclar for the treatment of eye burns. Specifically, Holoclar is intended for treatment of limbal stem-cell …

Feb 20, 2015 · Underlying Holoclar ® are more than twenty years of excellence in research, conducted by a team of internationally renowned scientists in the field of epithelial stem cell biology aimed at …

In February 2015, Holoclar was the first stem cell-based medicine to receive authorization for commercial use throughout the European Union. Injury to the eye can destroy limbal stem cells …

The Holoclar experience exem-plifies the value of positive inter-action between academia, industry and regulators in a highly complex area such as stem cell therapy in a rare and unmet medical need lead …

Holoclar is the first EU-approved stem cell product for limbal stem cell deficiency, demonstrating unique regulatory pathways. The treatment successfully restored corneal epithelium in 72.1% of 148 …

Dec 27, 2017 · Holoclar (manufactured by Holostem Terapie Avanzate S.R.L. and originally developed by Professors Graziella Pellegrini and Michele De Luca) is a cell-based tissue engineered therapy …

La Agencia Europea del Medicamento (EMA) ha dado su visto bueno a Holoclar, la primera terapia basada en células madre, para el tratamiento de la deficiencia de células limbares en la córnea del …